Testen von Cabozantinib bei Patienten mit fortgeschrittenen neuroendokrinen und karzinoiden Tumoren der Bauchspeicheldrüse
Randomisierte, doppelblinde Phase-III-Studie zu Cabozantinib im Vergleich zu Placebo bei Patienten mit fortgeschrittenen neuroendokrinen Tumoren nach Progression unter vorheriger Therapie (CABINET)
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
- Neuroendokriner Tumor
- Funktionierender neuroendokriner Tumor der Bauchspeicheldrüse
- Neuroendokrine Lungenneoplasie mittleren Grades
- Lokal fortgeschrittener neuroendokriner Pankreastumor
- Lokal fortgeschrittenes, nicht resezierbares neuroendokrines Neoplasma des Verdauungssystems
- Niedriggradiger neuroendokriner Lungentumor
- Metastasierendes Verdauungssystem Neuroendokrine Neoplasie
- Metastasierender neuroendokriner Tumor des Verdauungssystems G1
- Metastasierender neuroendokriner Tumor der Bauchspeicheldrüse
- Neuroendokrine Neoplasie
- Nicht funktionierender neuroendokriner Tumor der Bauchspeicheldrüse
- Serotonin-produzierender neuroendokriner Tumor der Bauchspeicheldrüse
- Lokal fortgeschrittenes neuroendokrines Neoplasma der Lunge
- Metastasierendes neuroendokrines Lungenneoplasma
- Nicht resezierbares neuroendokrines Neoplasma der Lunge
- Lokal fortgeschrittenes neuroendokrines Neoplasma des Verdauungssystems
- Lokal fortgeschrittener neuroendokriner Tumor des Verdauungssystems G1
- Metastasierendes neuroendokrines Neoplasma der Bauchspeicheldrüse
- Nicht resektables neuroendokrines Neoplasma des Verdauungssystems
- Nicht resezierbarer neuroendokriner Tumor des Verdauungssystems G1
- Nicht resezierbare neuroendokrine Neoplasie der Bauchspeicheldrüse
- Neuroendokriner Lungentumor G2
- Metastasierter neuroendokriner Lungentumor
- Neuroendokriner Tumor der Lunge
- Neuroendokriner Tumor G2
- Metastasiertes neuroendokrines Thymus-Neoplasma
- Neuroendokriner Tumor der Thymusdrüse
- Nicht resezierbares neuroendokrines Neoplasma des Thymus
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To determine whether cabozantinib (cabozantinib S-malate) can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced pancreatic neuroendocrine tumors (NET) whose disease has progressed after prior therapy.
II. To determine whether cabozantinib can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced carcinoid tumors whose disease has progressed after prior therapy.
SECONDARY OBJECTIVES:
I. To determine whether cabozantinib can significantly improve overall survival (OS) compared to placebo in patients with advanced pancreatic NET whose disease has progressed after prior therapy.
II. To determine whether cabozantinib can significantly improve overall survival (OS) compared to placebo in patients with advanced carcinoid tumors whose disease has progressed after prior therapy.
III. To evaluate safety and tolerability of cabozantinib versus placebo in patients with advanced pancreatic NET using Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
IV. To evaluate safety and tolerability of cabozantinib versus placebo in patients with advanced carcinoid tumors using CTCAE and PRO-CTCAE.
V. To evaluate the overall radiographic response rate of cabozantinib versus placebo in patients with advanced pancreatic NET whose disease has progressed after prior therapy.
VI. To evaluate the overall radiographic response rate of cabozantinib versus placebo in patients with advanced carcinoid tumors whose disease has progressed after prior therapy.
OTHER OBJECTIVE:
I. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
QUALITY OF LIFE SUBSTUDY OBJECTIVE:
I. To compare overall quality of life, disease-related symptoms, and other domains between the two treatment groups (cabozantinib versus [vs.] placebo) within each cohort of patients (pancreatic NET vs. carcinoid tumor). (Quality of Life Substudy Objective - A021602-HO1)
POPULATION PHARMACOKINETICS SUBSTUDY OBJECTIVE:
I. To describe the population pharmacokinetic and exposure-response relationships of cabozantinib in patients with advanced neuroendocrine tumors. (Population Pharmacokinetics Substudy Objective - A021602-PP1)
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and computed tomography (CT), magnetic resonance imaging (MRI), and/or x-ray imaging during screening and on study.
ARM II: Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.
After completion of study treatment, patients are followed up every 12 weeks until disease progression or start of new anticancer therapy, and then every 6 months until 8 years after registration.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Alaska
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Katmai Oncology Group
-
-
Arizona
-
Kingman, Arizona, Vereinigte Staaten, 86401
- Kingman Regional Medical Center
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Mayo Clinic Hospital in Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Vereinigte Staaten, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Antioch, California, Vereinigte Staaten, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Arroyo Grande, California, Vereinigte Staaten, 93420
- PCR Oncology
-
Auburn, California, Vereinigte Staaten, 95602
- Sutter Auburn Faith Hospital
-
Berkeley, California, Vereinigte Staaten, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burlingame, California, Vereinigte Staaten, 94010
- Mills-Peninsula Medical Center
-
Duarte, California, Vereinigte Staaten, 91010
- City of Hope Comprehensive Cancer Center
-
Dublin, California, Vereinigte Staaten, 94568
- Epic Care-Dublin
-
Emeryville, California, Vereinigte Staaten, 94608
- Epic Care Partners in Cancer Care
-
Fremont, California, Vereinigte Staaten, 94538
- Kaiser Permanente-Fremont
-
Fremont, California, Vereinigte Staaten, 94538
- Palo Alto Medical Foundation-Fremont
-
Fresno, California, Vereinigte Staaten, 93720
- Kaiser Permanente-Fresno
-
Martinez, California, Vereinigte Staaten, 94553-3156
- Contra Costa Regional Medical Center
-
Marysville, California, Vereinigte Staaten, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Vereinigte Staaten, 95355
- Memorial Medical Center
-
Modesto, California, Vereinigte Staaten, 95356
- Kaiser Permanente-Modesto
-
Mountain View, California, Vereinigte Staaten, 94040
- Palo Alto Medical Foundation-Camino Division
-
Oakland, California, Vereinigte Staaten, 94611
- Kaiser Permanente-Oakland
-
Oakland, California, Vereinigte Staaten, 94609
- Alta Bates Summit Medical Center - Summit Campus
-
Palo Alto, California, Vereinigte Staaten, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Vereinigte Staaten, 94301
- Palo Alto Medical Foundation Health Care
-
Redwood City, California, Vereinigte Staaten, 94063
- Kaiser Permanente-Redwood City
-
Richmond, California, Vereinigte Staaten, 94801
- Kaiser Permanente-Richmond
-
Roseville, California, Vereinigte Staaten, 95661
- Kaiser Permanente-Roseville
-
Roseville, California, Vereinigte Staaten, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Vereinigte Staaten, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Vereinigte Staaten, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Vereinigte Staaten, 95823
- Kaiser Permanente-South Sacramento
-
Salinas, California, Vereinigte Staaten, 93901
- Salinas Valley Memorial
-
San Francisco, California, Vereinigte Staaten, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Vereinigte Staaten, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Vereinigte Staaten, 94115
- California Pacific Medical Center-Pacific Campus
-
San Jose, California, Vereinigte Staaten, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Vereinigte Staaten, 94577
- Kaiser Permanente San Leandro
-
San Mateo, California, Vereinigte Staaten, 94401
- Mills Health Center
-
San Rafael, California, Vereinigte Staaten, 94903
- Kaiser San Rafael-Gallinas
-
San Rafael, California, Vereinigte Staaten, 94903
- Kaiser Permanente-San Rafael
-
Santa Clara, California, Vereinigte Staaten, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Cruz, California, Vereinigte Staaten, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Kaiser Permanente-Santa Rosa
-
South San Francisco, California, Vereinigte Staaten, 94080
- Kaiser Permanente-South San Francisco
-
Stockton, California, Vereinigte Staaten, 95210
- Kaiser Permanente-Stockton
-
Sunnyvale, California, Vereinigte Staaten, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vacaville, California, Vereinigte Staaten, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Vereinigte Staaten, 94589
- Kaiser Permanente-Vallejo
-
Vallejo, California, Vereinigte Staaten, 94589
- Sutter Solano Medical Center/Cancer Center
-
Walnut Creek, California, Vereinigte Staaten, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Boulder, Colorado, Vereinigte Staaten, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Vereinigte Staaten, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Vereinigte Staaten, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Vereinigte Staaten, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Vereinigte Staaten, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Vereinigte Staaten, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Englewood, Colorado, Vereinigte Staaten, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Vereinigte Staaten, 80113
- Swedish Medical Center
-
Golden, Colorado, Vereinigte Staaten, 80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction, Colorado, Vereinigte Staaten, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Greeley, Colorado, Vereinigte Staaten, 80631
- Banner North Colorado Medical Center
-
Lafayette, Colorado, Vereinigte Staaten, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Littleton, Colorado, Vereinigte Staaten, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Vereinigte Staaten, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Vereinigte Staaten, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, Vereinigte Staaten, 80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge, Colorado, Vereinigte Staaten, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Danbury, Connecticut, Vereinigte Staaten, 06810
- Danbury Hospital
-
Norwalk, Connecticut, Vereinigte Staaten, 06856
- Norwalk Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Aventura, Florida, Vereinigte Staaten, 33180
- GenesisCare USA - Aventura FP
-
Aventura, Florida, Vereinigte Staaten, 33180
- GenesisCare USA - Aventura
-
Boca Raton, Florida, Vereinigte Staaten, 33431
- GenesisCare USA - Boca Ration FP06
-
Fort Myers, Florida, Vereinigte Staaten, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Hollywood, Florida, Vereinigte Staaten, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Vereinigte Staaten, 32224-9980
- Mayo Clinic in Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Emory Saint Joseph's Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Vereinigte Staaten, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Vereinigte Staaten, 96819
- Kaiser Permanente Moanalua Medical Center
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Pali Momi Medical Center
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Vereinigte Staaten, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Kootenai Health - Coeur d'Alene
-
Emmett, Idaho, Vereinigte Staaten, 83617
- Walter Knox Memorial Hospital
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Idaho Urologic Institute-Meridian
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Vereinigte Staaten, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Vereinigte Staaten, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Vereinigte Staaten, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Vereinigte Staaten, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Illinois CancerCare-Carthage
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois
-
Danville, Illinois, Vereinigte Staaten, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Vereinigte Staaten, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Loyola University Medical Center
-
New Lenox, Illinois, Vereinigte Staaten, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Vereinigte Staaten, 60462
- University of Chicago Medicine-Orland Park
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Vereinigte Staaten, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Springfield Clinic
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Carle Cancer Center
-
Washington, Illinois, Vereinigte Staaten, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
South Bend, Indiana, Vereinigte Staaten, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Bettendorf, Iowa, Vereinigte Staaten, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, Vereinigte Staaten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Vereinigte Staaten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Vereinigte Staaten, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Vereinigte Staaten, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Vereinigte Staaten, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Vereinigte Staaten, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70808
- Our Lady of the Lake Physician Group
-
Covington, Louisiana, Vereinigte Staaten, 70433
- Northshore Oncology Associates-Covington
-
Houma, Louisiana, Vereinigte Staaten, 70360
- Oncology Center of The South Incorporated
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Vereinigte Staaten, 02118
- Boston Medical Center
-
Burlington, Massachusetts, Vereinigte Staaten, 01805
- Lahey Clinic
-
-
Michigan
-
Adrian, Michigan, Vereinigte Staaten, 49221
- Hickman Cancer Center
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, Vereinigte Staaten, 49017
- Bronson Battle Creek
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Vereinigte Staaten, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Vereinigte Staaten, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Vereinigte Staaten, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- McLaren Cancer Institute-Clarkston
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Vereinigte Staaten, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, Vereinigte Staaten, 48054
- Henry Ford River District Hospital
-
Farmington Hills, Michigan, Vereinigte Staaten, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Vereinigte Staaten, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Vereinigte Staaten, 48532
- Singh and Arora Hematology Oncology PC
-
Flint, Michigan, Vereinigte Staaten, 48503
- Hurley Medical Center
-
Flint, Michigan, Vereinigte Staaten, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Vereinigte Staaten, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Vereinigte Staaten, 48503
- Cancer Hematology Centers - Flint
-
Grosse Pointe Woods, Michigan, Vereinigte Staaten, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, Vereinigte Staaten, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, Vereinigte Staaten, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Vereinigte Staaten, 49009
- Beacon Kalamazoo Cancer Center
-
Lansing, Michigan, Vereinigte Staaten, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Vereinigte Staaten, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, Vereinigte Staaten, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, Vereinigte Staaten, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, Vereinigte Staaten, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Monroe, Michigan, Vereinigte Staaten, 48162
- Toledo Clinic Cancer Centers-Monroe
-
Mount Clemens, Michigan, Vereinigte Staaten, 48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant, Michigan, Vereinigte Staaten, 48858
- McLaren Cancer Institute-Central Michigan
-
Petoskey, Michigan, Vereinigte Staaten, 49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Hope Cancer Center
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Port Huron, Michigan, Vereinigte Staaten, 48060
- McLaren-Port Huron
-
Port Huron, Michigan, Vereinigte Staaten, 48060
- Lake Huron Medical Center
-
Port Huron, Michigan, Vereinigte Staaten, 48060
- Huron Medical Center PC
-
Rochester Hills, Michigan, Vereinigte Staaten, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, Vereinigte Staaten, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Vereinigte Staaten, 48601
- MyMichigan Medical Center Saginaw
-
Sterling Heights, Michigan, Vereinigte Staaten, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, Vereinigte Staaten, 48764
- MyMichigan Medical Center Tawas
-
Warren, Michigan, Vereinigte Staaten, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, Vereinigte Staaten, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, Vereinigte Staaten, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, Vereinigte Staaten, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, Vereinigte Staaten, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, Vereinigte Staaten, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Vereinigte Staaten, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Bemidji, Minnesota, Vereinigte Staaten, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Mercy Hospital
-
Deer River, Minnesota, Vereinigte Staaten, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Essentia Health Cancer Center
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Vereinigte Staaten, 55432
- Unity Hospital
-
Hibbing, Minnesota, Vereinigte Staaten, 55746
- Essentia Health Hibbing Clinic
-
Maple Grove, Minnesota, Vereinigte Staaten, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Vereinigte Staaten, 55454
- Health Partners Inc
-
New Ulm, Minnesota, Vereinigte Staaten, 56073
- New Ulm Medical Center
-
Robbinsdale, Minnesota, Vereinigte Staaten, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- United Hospital
-
Sandstone, Minnesota, Vereinigte Staaten, 55072
- Essentia Health Sandstone
-
Shakopee, Minnesota, Vereinigte Staaten, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Vereinigte Staaten, 55082
- Lakeview Hospital
-
Virginia, Minnesota, Vereinigte Staaten, 55792
- Essentia Health Virginia Clinic
-
Waconia, Minnesota, Vereinigte Staaten, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Vereinigte Staaten, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Vereinigte Staaten, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Vereinigte Staaten, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Bonne Terre, Missouri, Vereinigte Staaten, 63628
- Parkland Health Center-Bonne Terre
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Vereinigte Staaten, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Vereinigte Staaten, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Vereinigte Staaten, 63640
- Parkland Health Center - Farmington
-
Sainte Genevieve, Missouri, Vereinigte Staaten, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Vereinigte Staaten, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Vereinigte Staaten, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Vereinigte Staaten, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Vereinigte Staaten, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Vereinigte Staaten, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Vereinigte Staaten, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Vereinigte Staaten, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Vereinigte Staaten, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Great Falls Clinic
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Vereinigte Staaten, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Logan Health Medical Center
-
Missoula, Montana, Vereinigte Staaten, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Vereinigte Staaten, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
-
Nevada
-
Carson City, Nevada, Vereinigte Staaten, 89703
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Vereinigte Staaten, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Vereinigte Staaten, 89052
- Cancer and Blood Specialists-Henderson
-
Henderson, Nevada, Vereinigte Staaten, 89052
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Vereinigte Staaten, 89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson, Nevada, Vereinigte Staaten, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Vereinigte Staaten, 89074
- Oncology Las Vegas - Henderson
-
Las Vegas, Nevada, Vereinigte Staaten, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Vereinigte Staaten, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Vereinigte Staaten, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Vereinigte Staaten, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Vereinigte Staaten, 89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Vereinigte Staaten, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Vereinigte Staaten, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89106
- Cancer and Blood Specialists-Shadow
-
Las Vegas, Nevada, Vereinigte Staaten, 89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas, Nevada, Vereinigte Staaten, 89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas, Nevada, Vereinigte Staaten, 89121
- Cancer Therapy and Integrative Medicine
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- Cancer and Blood Specialists-Tenaya
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas, Nevada, Vereinigte Staaten, 89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Vereinigte Staaten, 89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Vereinigte Staaten, 89102
- Desert West Surgery
-
Las Vegas, Nevada, Vereinigte Staaten, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89169
- University Cancer Center
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- Oncology Las Vegas - Tenaya
-
Las Vegas, Nevada, Vereinigte Staaten, 89183
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Vereinigte Staaten, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Vereinigte Staaten, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Vereinigte Staaten, 89503
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Vereinigte Staaten, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Nashua, New Hampshire, Vereinigte Staaten, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Basking Ridge, New Jersey, Vereinigte Staaten, 07920
- Memorial Sloan Kettering Basking Ridge
-
Englewood, New Jersey, Vereinigte Staaten, 07631
- Englewood Hospital and Medical Center
-
Middletown, New Jersey, Vereinigte Staaten, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Vereinigte Staaten, 07645
- Memorial Sloan Kettering Bergen
-
Paramus, New Jersey, Vereinigte Staaten, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Vereinigte Staaten, 07450
- Valley Health System Ridgewood Campus
-
Wayne, New Jersey, Vereinigte Staaten, 07470
- Valley Medical Group - Wayne Multispecialty Practice
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87109
- New Mexico Oncology Hematology Consultants
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Vereinigte Staaten, 87110
- Presbyterian Kaseman Hospital
-
Rio Rancho, New Mexico, Vereinigte Staaten, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Auburn, New York, Vereinigte Staaten, 13021
- Hematology Oncology Associates of Central New York-Auburn
-
Buffalo, New York, Vereinigte Staaten, 14263
- Roswell Park Cancer Institute
-
Camillus, New York, Vereinigte Staaten, 13031
- Hematology Oncology Associates of CNY at Camillus
-
Commack, New York, Vereinigte Staaten, 11725
- Memorial Sloan Kettering Commack
-
East Syracuse, New York, Vereinigte Staaten, 13057
- Hematology Oncology Associates of Central New York-East Syracuse
-
Harrison, New York, Vereinigte Staaten, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Vereinigte Staaten, 10029
- Mount Sinai Hospital
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
Uniondale, New York, Vereinigte Staaten, 11553
- Memorial Sloan Kettering Nassau
-
Webster, New York, Vereinigte Staaten, 14580
- Wilmot Cancer Institute at Webster
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Clinton, North Carolina, Vereinigte Staaten, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Vereinigte Staaten, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Kinston, North Carolina, Vereinigte Staaten, 28501
- ECU Health Oncology Kinston
-
Washington, North Carolina, Vereinigte Staaten, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Beachwood, Ohio, Vereinigte Staaten, 44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre, Ohio, Vereinigte Staaten, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Miami Valley Hospital South
-
Chillicothe, Ohio, Vereinigte Staaten, 45601
- Adena Regional Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case Western Reserve University
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Vereinigte Staaten, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Vereinigte Staaten, 43228
- Doctors Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43215
- Grant Medical Center
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Premier Blood and Cancer Center
-
Delaware, Ohio, Vereinigte Staaten, 43015
- Delaware Health Center-Grady Cancer Center
-
Franklin, Ohio, Vereinigte Staaten, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Mansfield, Ohio, Vereinigte Staaten, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, Vereinigte Staaten, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Vereinigte Staaten, 43302
- OhioHealth Marion General Hospital
-
Maumee, Ohio, Vereinigte Staaten, 43537
- Toledo Clinic Cancer Centers-Maumee
-
Maumee, Ohio, Vereinigte Staaten, 43537
- Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
-
Mentor, Ohio, Vereinigte Staaten, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middleburg Heights, Ohio, Vereinigte Staaten, 44130
- UH Seidman Cancer Center at Southwest General Hospital
-
Newark, Ohio, Vereinigte Staaten, 43055
- Licking Memorial Hospital
-
Parma, Ohio, Vereinigte Staaten, 44129
- University Hospitals Parma Medical Center
-
Perrysburg, Ohio, Vereinigte Staaten, 43551
- Mercy Health - Perrysburg Hospital
-
Portsmouth, Ohio, Vereinigte Staaten, 45662
- Southern Ohio Medical Center
-
Toledo, Ohio, Vereinigte Staaten, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Vereinigte Staaten, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Vereinigte Staaten, 45373
- Upper Valley Medical Center
-
Wadsworth, Ohio, Vereinigte Staaten, 44281
- University Hospitals Sharon Health Center
-
Westlake, Ohio, Vereinigte Staaten, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
Zanesville, Ohio, Vereinigte Staaten, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Vereinigte Staaten, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Baker City, Oregon, Vereinigte Staaten, 97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Clackamas, Oregon, Vereinigte Staaten, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Vereinigte Staaten, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Vereinigte Staaten, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18017
- Lehigh Valley Hospital - Muhlenberg
-
East Stroudsburg, Pennsylvania, Vereinigte Staaten, 18301
- Pocono Medical Center
-
Erie, Pennsylvania, Vereinigte Staaten, 16544
- Saint Vincent Hospital
-
Hazleton, Pennsylvania, Vereinigte Staaten, 18201
- Lehigh Valley Hospital-Hazleton
-
Jefferson Hills, Pennsylvania, Vereinigte Staaten, 15025
- Jefferson Hospital
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- West Penn Hospital
-
Wexford, Pennsylvania, Vereinigte Staaten, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Vereinigte Staaten, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Vereinigte Staaten, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, Vereinigte Staaten, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Vereinigte Staaten, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Utah
-
Farmington, Utah, Vereinigte Staaten, 84025
- Farmington Health Center
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84106
- University of Utah Sugarhouse Health Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98101
- Virginia Mason Medical Center
-
-
West Virginia
-
Huntington, West Virginia, Vereinigte Staaten, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Vereinigte Staaten, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Duluth Clinic Ashland
-
Eau Claire, Wisconsin, Vereinigte Staaten, 54701
- Marshfield Medical Center-EC Cancer Center
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Vereinigte Staaten, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Vereinigte Staaten, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Vereinigte Staaten, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Vereinigte Staaten, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- ProHealth Waukesha Memorial Hospital
-
Weston, Wisconsin, Vereinigte Staaten, 54476
- Marshfield Medical Center - Weston
-
-
Wyoming
-
Cody, Wyoming, Vereinigte Staaten, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Vereinigte Staaten, 82801
- Welch Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Documentation of Disease:
-
Histologic Documentation: Well- or moderately-differentiated neuroendocrine tumors of pancreatic and non-pancreatic (i.e. carcinoid) origin by local pathology
- The pathology report must state ONE of the following: 1) well- or moderately-differentiated neuroendocrine tumor, 2) low- or intermediate-grade neuroendocrine tumor, or 3) carcinoid tumor or atypical carcinoid tumor; documentation of histology from a primary or metastatic site is allowed
- Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma without specification of differentiation status, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible. Patients with well-differentiated grade 3 neuroendocrine tumor are eligible
-
Stage: Locally advanced/unresectable or metastatic disease
-
Tumor Site: Histological documentation of neuroendocrine tumor of pancreatic, gastrointestinal (GI), lung, thymus, other, or unknown primary site; GI, lung, thymus, other, and unknown primary NETs will enroll in the carcinoid tumor cohort of the study
- Functional (i.e., associated with symptoms or clinical syndrome related to hormone secretion by tumor) or nonfunctional tumors are allowed
-
Radiologic Evaluation: Target lesions must have shown evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria in the 12 months prior to registration; the radiologic images, imaging reports, and clinic notes indicating growth of existing lesions, development of new lesions, or treatment changes must be submitted
-
-
Measurable Disease
- Patients must have measurable disease per RECIST 1.1 by computer tomography (CT) scan or magnetic resonance imaging (MRI)
- Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes); non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
-
Prior Treatment
- Patient must have experienced disease progression after receiving or intolerance leading to treatment discontinuation of at least one Food and Drug Administration (FDA)-approved line of therapy (except somatostatin analogs); prior lines of therapy must include one of the following: everolimus, sunitinib, or lutetium Lu 177 dotatate in patients with pancreatic NET; everolimus in patients with lung NET; everolimus or lutetium Lu 177 dotatate in patients with gastrointestinal NET
- Prior treatment (except somatostatin analogs) with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, and/or radiation must be completed at least 28 days prior to registration
- Prior treatment with somatostatin analogs is allowed, and continuation of treatment with somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months
- Prior systemic treatment with radionuclide therapy must be completed at least 6 weeks prior to registration
- Prior treatment with hepatic artery embolization (including bland embolization, chemoembolization, and selective internal radiation therapy) or ablative therapies is allowed if measurable disease remains outside of the treated area or if there is documented disease progression in a treated site; prior liver-directed or other ablative treatment must be completed at least 28 days prior to registration
- Prior treatment with cabozantinib is not allowed
- Patients should have resolution of any toxic effects of prior therapy (except alopecia and fatigue) to National Cancer Institute (NCI) CTCAE, version 5.0, grade 1 or less
- Patients must have completed any major surgery at least 12 weeks prior to registration and any minor surgery (including uncomplicated tooth extractions) at least 28 days prior to registration; complete wound healing from major surgery must have occurred at least 28 days prior to registration, and complete wound healing from minor surgery must have occurred at least 10 days prior to registration
-
Patient History
- No class III or IV congestive heart failure (CHF) within 6 months of registration
- No clinically significant cardiac arrhythmia within 6 months of registration
- No unstable angina or myocardial infarction (MI) within 6 months of registration
- No thromboembolic events within 6 months of registration (including [incl.] stroke, transient ischemic attack [TIA], deep vein thrombosis [DVT], & pulmonary embolism [PE])
- No known history of congenital long QT syndrome
- No uncontrolled hypertension within 14 days of registration (defined as systolic blood pressure [SBP] >= 150 mmHg and/or diastolic blood pressure [DBP] >= 90 mmHg despite optimal medical management)
- No clinically significant GI bleeding within 6 months of registration
- No clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding within 6 months of registration including, but not limited to: active peptic ulcer, known endoluminal metastatic lesion(s) with history of bleeding, inflammatory bowel disease, or other gastrointestinal conditions with increased risk of perforation
- No GI perforation within 6 months of registration
- No known tumor with invasion into the GI tract from the outside causing increased risk of perforation or bleeding within 28 days of registration
- No radiologic or clinical evidence of pancreatitis
- No known cavitary lung lesions
- No known endobronchial lesions involving the main or lobar bronchi and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage; (CT with contrast is recommended to evaluate such lesions)
- No hemoptysis greater than 1/2 teaspoon (2.5 mL) or any other signs of pulmonary hemorrhage within the 3 months prior to registration
- No known tumor invading or encasing any major blood vessels
- No history of non-healing wounds or ulcers within 28 days of registration
- No history of fracture within 28 days of registration
- No brain metastases or cranial epidural disease unless adequately treated, stable, and off steroid support for at least 4 weeks prior to registration
- No known medical condition causing an inability to swallow oral formulations of agents
- No history of allergic reaction attributed to compounds of similar chemical or biological composition to cabozantinib/placebo
- No "currently active" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ; patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for >= 3 years
-
Concomitant Medications
- Other planned concurrent investigational agents or other tumor directed therapies (chemotherapy, radiation) are not allowed while on this study
- Concurrent use of somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months
- Full dose oral anticoagulation/antiplatelet therapy is not permitted; low dose aspirin =< 81 mg/day is allowed; anticoagulation with therapeutic doses of low molecular weight heparin (LMWH) is allowed in patients who are on a stable dose of LMWH for at least 6 weeks prior to registration; treatment with warfarin is not allowed; anticoagulation in patients with brain metastases is not permitted
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed; patients must discontinue the drug at least 14 days prior to registration on the study
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed; patients must discontinue the drug at least 14 days prior to registration on the study
-
Not pregnant and not nursing
- Women of childbearing potential must have a negative pregnancy test done =< 14 days prior to registration
- A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e. has had menses at any time in the preceding 12 consecutive months)
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status: 0-2
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Hemoglobin >= 9 g/dL
-
Platelet count >= 100,000/mm^3
-
Prothrombin time (PT)/ international normalized ratio (INR), partial thromboplastin time (PTT) < 1.3 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 3 x ULN
-
Total bilirubin =< 1.5 x ULN
- Except in the case of Gilbert disease, in which case total bilirubin must be =< 3 x ULN
-
Creatinine =< 1.5 mg/dL OR creatinine clearance >= 45 mL/min
-
Albumin >= 2.8 g/dL
-
Potassium within normal limits (WNL)
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal thyroid stimulating hormone (TSH), if free T4 is normal and patient is clinically euthyroid, patient is eligible
-
Phosphorus WNL
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
-
Calcium WNL
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
-
Magnesium WNL
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
-
Urine protein to creatinine (UPC) ratio =< 1
-
QT interval corrected for heart rate using Fridericia's formula (QTcF) =< 500 msec
-
TSH WNL
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Arm I (cabozantinib S-malate)
Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study. |
Ancillary studies
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Given PO
Andere Namen:
Undergo blood and urine sample collection
Andere Namen:
Undergo x-ray
Andere Namen:
|
|
Placebo-Komparator: Arm II (placebo)
Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression. |
Ancillary studies
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Given PO Undergo blood and urine sample collection
Andere Namen:
Undergo x-ray
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free Survival (PFS)
Zeitfenster: 36 months
|
Will be assessed per Response Evaluation Criteria in Solid Tumors 1.1 determined by retrospective independent central review. Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The stratification factors will be used for the analysis. The hazard ratio (HR) for PFS will be estimated using a stratified Cox proportional hazards model, and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median PFS for each treatment arm. |
36 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival (OS)
Zeitfenster: 60 months
|
The analyses for OS will follow intent-to-treat (ITT) principle and will be conducted separately within each cohort (pancreatic neuroendocrine tumor [NET] and carcinoid tumor). The distribution of OS will be estimated using the method of Kaplan-Meier. The median OS, along with the 95% CI, will be estimated by the two treatment groups. Overall survival will be compared between treatment arms using the stratified log-rank test at a one-sided cumulative 2.5% level of significance. The stratified Cox regression will be used to estimate the HR of OS, along with the 95% CI. A hierarchical approach will be used to control for family-wise type-I error rate, therefore OS will be formally statistically tested only if the primary efficacy endpoint, PFS, is statistically significantly different between the two treatment groups. |
60 months
|
|
Number of Patients Experiencing Grade 3+ Adverse Events (AEs) Graded According to the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Zeitfenster: 60 months
|
For CTCAE data, the frequency tables will be reviewed to determine the patterns. The overall adverse event rates will be compared between treatment groups using Chi-square test (or Fisher's exact test if the data in contingency table is sparse). PRO-CTCAE data will, at minimum, be analyzed similarly to CTCAE data. The initial analysis of each PRO-CTCAE item will use all available scores in an analysis which mirrors the approach used for the CTCAE data. Supplemental analysis will use model-based multiple imputation incorporating baseline patient characteristics and physician-rated performance status. CTCAE data may be incorporated as auxiliary data into multiple imputation models for AEs which are captured by both PRO-CTCAE and CTCAE. Results from supplemental analysis will be descriptively compared to the results of the initial analysis to assess the robustness of results to missing data. Additional analyses of PRO-CTCAE data beyond those specified above may be undertaken. |
60 months
|
|
Radiographic Response Rate
Zeitfenster: 36 months
|
Will be defined as the proportion of patients in each arm whose best response is either complete response (CR) or partial response (PR). Radiographic response rate for both cohorts: the analyses for confirmed radiographic response rate will follow the ITT principle and will be conducted separately within each cohort (pancreatic NET and carcinoid tumor). The proportion of patients with either confirmed CR or confirmed PR as their best response will be estimated using point estimates and 95% confidence intervals. Radiographic response rate will be compared between treatment arms using the 2-sample z-test to compare sample proportion at a one-sided 2.5% level of significance. |
36 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Jennifer A Chan, Alliance for Clinical Trials in Oncology
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.
- Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13;392(7):653-665. doi: 10.1056/NEJMoa2403991. Epub 2024 Sep 16.
- Strosberg JR, Zemla T, Geyer S, Pulsipher S, Ou FS, Behr S, Raj N, Vijayvergia N, Dasari A, O'Reilly EM, Meyerhardt JA, Wolin EM, Halfdanarson TR, Chan JA. Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Endocr Relat Cancer. 2026 Jan 24;33(1):e250415. doi: 10.1530/ERC-25-0415. Print 2026 Jan 1.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Neubildungen nach Standort
- Neubildungen
- Neubildungen nach histologischem Typ
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Neubildungen, Drüsen und Epithelien
- Adenom
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Neoplasmen der Bauchspeicheldrüse
- Neuroendokrine Tumoren
- Adenom, Inselzelle
- Nicht funktionierender endokriner Tumor der Bauchspeicheldrüse
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Physikalische Phänomene
- Ausrüstung und Vorräte
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Elektromagnetische Phänomene
- Magnetische Phänomene
- Elektromagnetische Strahlung
- Strahlung
- Strahlung, ionisieren
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Röntgenaufnahmen
- Cabozantinib
- Phantome, Bildgebung
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NCI-2017-02297
- U10CA180821 (US NIH Stipendium/Vertrag)
- NCI-2017-02297 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- A021602 (Andere Kennung: CTEP)
- A021602 (Andere Kennung: Alliance for Clinical Trials in Oncology)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .